Lake Street raised the firm’s price target on Personalis (PSNL) to $9 from $7 and keeps a Buy rating on the shares after the company reported preliminary Q4 revenue ahead the firm’s estimate and consensus. With cash to breakeven, a strong commercial partner, “robust” clinical data, and the potential for multiple reimbursement approvals, the firm views 2025 as “another transformative year” for Personalis, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- Personalis reports preliminary Q4 revenue $16.8M, consensus $15.5M
- Personalis raises FY24 revenue view to $84.6M from $83M-$84M
- Personalis up 3% at $6.15 after Q4 pre-announcement, FY24 guidance increase
- Personalis price target raised to $8 from $7 at BTIG
- Personalis price target raised to $11 from $9 at H.C. Wainwright